MDRT sponsored the “Life Insurance Company of the Year” award category which was awarded to HSBC Life (International) Limited.

SINGAPORE, Nov. 6, 2025 /PRNewswire/ — MDRT (Million Dollar Round Table), The Premier Association of Financial Professionals^®, was proud to sponsor the Asia Insurance Review‘s 29th Asia Insurance Industry Awards’ (AIIA) “Life Insurance Company of the Year” category, which was awarded to HSBC Life (International) Limited on Monday, 3 November at the Awards Ceremony at Marina Bay Sands Expo & Convention Centre, Singapore.

For more than a decade, MDRT has worked with the Asia Insurance Review to support and promote the financial services profession. This AIIA sponsorship reinforces MDRT’s commitment to the growth of companies and advisors across the region and celebrating their success.

“MDRT remains dedicated to empowering financial professionals with the tools and inspiration they need to thrive,” says MDRT Chief Executive Officer, Stephen P. Stahr, who presented the award. “Our sponsorship of the 2025 AIIA ‘Life Insurance Company of the Year’ Award celebrates organizations that set the benchmark for success in life insurance distribution by upholding professionalism and driving meaningful contributions to clients, advisors, and the industry as a whole.”

While MDRT membership requirements have a foundation in life insurance, they have expanded into more comprehensive and sophisticated financial planning. By embracing diverse distribution channels—agency, financial advisory, bancassurance, and other open-architecture partnerships—MDRT’s relevance and importance have grown across global markets, especially in Asia. MDRT is excited to drive further growth in the region through several endeavors, including its AIIA sponsorship.

For almost a century, MDRT has been a member-driven network of leading insurance and financial services professionals who serve their clients with the highest standards of ethics, knowledge, service and productivity. Today, MDRT has members from more than 80 nations and territories and nearly 700 companies, and seven Asia-Pacific markets are among the top 10 in total MDRT membership.

MDRT opened the Asia-Pacific headquarters in Singapore in 2023 to better serve its members and companies in the region. It liaises with MDRT’s U.S. headquarters and satellite offices in China and India to improve member resources and benefits and support local and regional leaders with events across Asia.

MDRT congratulates HSBC Life (International) Limited again on their accomplishment and invite others to apply to the “Life Insurance Company of the Year Award” which will be sponsored again by MDRT in 2026.

About MDRT

Founded in 1927, MDRT (Million Dollar Round Table), The Premier Association of Financial Professionals^®, is a global, independent association of the world’s leading life insurance and financial services professionals from more than 80 nations and territories and nearly 700 companies. MDRT members demonstrate exceptional professional knowledge, strict ethical conduct and outstanding client service. MDRT membership is recognized internationally as the standard of excellence in the life insurance and financial services business. For more information, please visit www.mdrt.org.

Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal “Vaccines”.

LOS ANGELES, Nov. 6, 2025 /PRNewswire/ — Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthrough: its next-generation immune cell therapy led to complete regression of both primary and metastatic pancreatic tumors in humanized mouse models.

Images of control and 2nd Gen treatment condition mice using in vivo imaging system. Live imaging system was utilized to capture the tumor growth at various timepoints. The DC treated mouse showed absent signals of tumor at 5-week post dosing.

The study was published in a new Brief Report in Vaccines on November 2, 2025. The peer-reviewed Brief Report details the development of a second-generation, clinical-grade DC construct that achieved complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models. Pancreatic cancer is one of the deadliest cancers, often diagnosed late and resistant to conventional treatments. Lunai’s therapy uses engineered dendritic cells — specialized immune cells created from stem cells — that are genetically enhanced to activate the body’s immune system against cancer. This publication details a second-generation, clinical-compliant version of this platform, with the provided evidence critical in advancing ongoing partnering conversations for the therapy.

This new publication builds on Lunai’s earlier study (Vaccines 2025 Jul 12;13(7):749; doi:10.3390/vaccines13070749), which first demonstrated potent anti-tumor activity of CD34+ hematopoietic stem cell (HSC)-derived DCs engineered to overexpress CD40L, CD93, and CXCL13 in humanized mouse models of pancreatic cancer. While the initial study utilized a research-grade lentiviral vector, the latest report describes an optimized, clinically compliant construct that preserves equivalent efficacy while improving design and manufacturing attributes to support future clinical translation.

The second-generation construct features a strong mammalian promoter and enhanced genetic elements to drive expression of key immune-modulating molecules. In preclinical humanized models, Lunai’s next-generation DC therapy triggered robust activation of cytotoxic T cells and NK cells and led to complete regression of both primary and metastatic pancreatic tumors. These findings mirrored the outcomes achieved with the original research-grade product. While the allogeneic DC product has been evaluated in pancreatic cancer models, its therapeutic potential extends to a broad range of solid tumors.

“These findings demonstrate that our vector optimization strategy maintains therapeutic potency while bringing our allogeneic DC platform to the threshold of IND-enabling studies,” said David Weinstein, CEO of Lunai Bioworks. “This represents an important inflection point as we move from research innovation to clinical translation—positioning Lunai at the forefront of next-generation cell-based immunotherapies.”

The full article, titled “Modified Hematopoietic Stem Cell-Derived Dendritic Cell Therapy Retained Tumor-Inhibitory Function and Led to Regression of Primary and Metastatic Pancreatic Tumors in Humanized Mouse Models,” is available in Vaccines (https://www.mdpi.com/2076-393X/13/11/1131).

About Lunai
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats. For more visit www.lunaibioworks.com.

Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future operations, plans, and market expectations. These statements are based on current assumptions and beliefs and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “plan,” “estimate,” and similar expressions are intended to identify forward-looking statements. Actual results may differ due to factors beyond the Company’s control. You should not place undue reliance on these statements, which speak only as of the date of this release. For additional information about risks and uncertainties that could affect the Company, please refer to its filings with the Securities and Exchange Commission at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

The Ritz-Carlton Spa introduces Southeast Asia’s first exclusive partnership with EPICUTIS^®, pharmaceutical-grade, science-backed skincare

SINGAPORE, Nov. 6, 2025 /PRNewswire/ — The Ritz-Carlton, Millenia Singapore is pleased to announce the Southeast Asia debut of innovative, science-driven skincare brand EPICUTIS^®, developed by biotech innovator Signum Biosciences. In this exclusive partnership, The Ritz-Carlton Spa Singapore has been designated as the brand’s flagship property in the region, where holistic harmony intertwines with the forefront of skincare innovation.

Elevating Luxury Wellness with Science
This collaboration is a significant step for The Ritz-Carlton Spa, positioning it as the first luxury spa in Southeast Asia to feature the cutting-edge EPICUTIS^® skincare line. As the luxury hospitality sector increasingly embraces integrative health and holistic wellness, The Ritz-Carlton Spa’s latest offerings seamlessly blend indulgent spa rituals with advanced molecular science. The exclusive menu of facials and advanced treatments features offerings designed to deliver not only refined comfort but also clinically-proven therapeutic efficacy to support a balanced and refined lifestyle, rooted in holistic well-being. This move underscores the hotel’s position as a forerunner in luxury hospitality, reflecting a keen understanding of evolving consumer preferences, where wellness, backed by performance and science, is increasingly embraced as an essential part of modern luxury living.

Peter Mainguy, General Manager of The Ritz-Carlton, Millenia Singapore commented: “At The Ritz-Carlton, we are committed to continuously innovating in anticipation of our guests’ evolving and often unspoken needs. Our exclusive partnership with EPICUTIS^® marks a new chapter in luxury wellness for Southeast Asia – one where cutting-edge skincare science meets holistic well-being. Together, we are redefining the standards of efficacy and experience, offering our guests visible, lasting results that embody both inner balance and outer radiance.”

Maxwell Stock, Founder & CEO of EPICUTIS^® shared: “Singapore is a hub of innovation, culture, and luxury, making it the perfect gateway for EPICUTIS^® into Southeast Asia. Partnering with The Ritz-Carlton, Millenia Singapore allows us to share our science-first philosophy with discerning travelers and locals who value both results and refinement.”

The EPICUTIS^® Science-first Philosophy
Adopting a science-first philosophy, EPICUTIS^® redefines clean beauty standards. Developed in one of the world’s most advanced scientific laboratories by renowned Princeton biophysicist Dr. Jeffry Stock, EPICUTIS^® is the first professional skincare line to apply pharmaceutical research technologies to topical formulations. In collaboration with master formulator Masanori Tamura, EPICUTIS^® delivers clean, clinically proven, performance-driven formulations featuring proprietary patented active ingredients — including TSC, Hyvia^®, and DSD* — designed to support skin health on a cellular level. Every EPICUTIS^® product is EWG Verified and made with 100% non-toxic ingredients are sourced and processed to meet medical-grade purity standards. Embracing a “less-is-more” approach, EPICUTIS^® is committed to full transparency. Each formula is crafted with minimal, clearly disclosed ingredients, free from unnecessary additives for maximum results. This ensures biocompatibility, safety, and efficacy, while significantly reducing the risk of adverse reaction — an approach that resonates with today’s wellness-focused traveler who prioritises skin longevity and holistic well-being.

Elevated Signature Spa Treatments by EPICUTIS^® include: 
Bespoke Facial: A fully customised facial tailored to individual skin’s unique needs with advanced pharmaceutical-grade EPICUTIS^® formulations to deliver targeted results, promoting optimal skin health and balance.

Signature Facial: An efficacious yet luxurious treatment designed to visibly brighten the complexion while strengthening the skin barrier. Powered by EPICUTIS^® patented ingredients, ABSO and Hyvia^®, this facial delivers long-lasting hydration, resilience and radiance.

Brightening Facial: A next-generation facial infused with antioxidant-rich actives to restore luminosity from within. This revitalising treatment helps even skin tone, boost clarity, and revive a dull complexion with scientifically proven EPICUTIS^® ingredients.

Mom-to-Be Ritual: A nurturing, pregnancy-safe treatment that calms inflammation, nourishes dry areas, promotes skin elasticity, and replenishes moisture for radiant, healthy skin, with the EPICUTIS^® Lipid Body Treatment.

Lipid Full Body Treatment: A full-body experience blending lymphatic drainage, exfoliation, and deep nourishment to restore and rejuvenate the skin, featuring the barrier-strengthening EPICUTIS^® Lipid Body Treatment.

The Spa Journey of Rejuvenation
Nestled amidst lush greenery and featuring an outdoor swimming pool, The Ritz-Carlton Spa Singapore offers a tranquil retreat in the heart of Marina Bay, where guests experience lasting wellness in a sanctuary of timeless elegance. Located across from the hotel’s state-of-the-art gym on Level One, the spa offers signature experiences designed to harmonise relaxation, wellness and indulgent pampering. Discover an extensive selection of massages, bespoke body therapies, and our signature Half-Day Luxury Spa Experience, a transformative experience crafted to renew both body and spirit. For guests seeking a romantic escape, our elegant Ritz-Carlton Spa Suite, provides a private haven within one of 10 serene treatment rooms, serving as the perfect setting to create unforgettable moments with your loved one.

Both his and her locker rooms offer whirlpools, steam rooms, saunas, shower facilities, and relaxation rooms with Zero Gravity recliners.

The Ritz-Carlton Spa Singapore is open daily, from 9 a.m. to 9 p.m. For enquiries and reservations, please contact (65) 6434-5203 or email rc.sinrz.spa@ritzcarlton.com. Visit us at www.ritzcarlton.com/en/hotels/singapore/spa.

*Scientific Terminology
TSC (tetramethylhexadecenyl succinoyl cysteine) is a novel molecule that acts as a super-lipid, dramatically improving skin’s natural barrier function while helping to shield it from a variety of environmental aggressors —including UV rays and pollution.

Hyvia^® a novel moisturizing agent derived from organic non-GMO chia seed oil, delivers stable potent omega-3 and omega-6 fatty acids—working at the cellular level to help boost hydration, calm inflammation and fight fine lines, wrinkles and other visible signs of skin aging.

DSD (disodium S-phytyl diglycoloylcysteine) is a powerful, proprietary antioxidant that protects against environmental stressors by blocking UV and pollution induced skin damage.

Press kit images are available for download here.

About The Ritz-Carlton, Millenia Singapore
Centrally located along Singapore’s Marina Bay, this 608-room luxury hotel continues to be distinguished by unparalleled hospitality synonymous with The Ritz-Carlton brand. Exciting local attractions such as Gardens by the Bay, the Art Science Museum, the Integrated Resorts and the Singapore Flyer are only minutes away, while over 2,000 shopping and dining options are accessible via a covered sky bridge.

Renowned for iconic views from its spacious guest rooms and suites, the hotel features an exclusive Club Lounge on Level 32. World-class dining options include Colony which showcases a true taste of Singapore, the one Michelin star Summer Pavilion, or the 1960s inspired Republic, which is ranked No.57 of Asia’s 50 Best Bars extended list 2024. Exclusive EPICUTIS^® facials and ESPA body treatments can be enjoyed at the award-winning Ritz-Carlton Spa.

About EPICUTIS^®
EPICUTIS^® is a science-based, luxury professional skincare line that treats skin health and not age. Honouring a commitment to clean beauty and minimal ingredients, offers science-based skincare using patented active ingredients in small-batch formulations created by expert formulator Masanori Tamura. EPICUTIS^®‘ novel ingredients are developed in-house by a team of scientists at Signum Biosciences utilizing technology discovered by Dr. Jeffry Stock at Princeton University. Signum Biosciences is a biopharmaceutical company focused on the discovery and development of innovative products to address major consumer and medical needs, and the development of compounds and botanical extracts that are mimetic of natural lipid ligands crucial to cellular regulation and signaling. To learn more about EPICUTIS^®, visit www.epicutis.com. To learn more about Signum Biosciences, visit www.signumbiosciences.com.

About The Ritz-Carlton Hotel Company, LLC
Delivering the Gold Standard in service in coveted destinations around the world, The Ritz-Carlton Hotel Company, LLC currently operates more than 120 hotels in over 35 countries and territories. From iconic urban destinations to stretches of paradise in untouched corners of the earth, The Ritz-Carlton offers the opportunity for true discovery and transformative escapes that stay with guests long after they depart. Committed to thoughtful innovation, The Ritz-Carlton encompasses two groundbreaking brand extensions, Ritz-Carlton Reserve and The Ritz-Carlton Yacht Collection. Ritz-Carlton Reserve is a collection of rare estates set apart from the world, where personalized care and cultural immersion are paramount. The Ritz-Carlton Yacht Collection translates the brand’s legendary service and hospitality for sea, reimagining the ultra-luxury cruising category. For more information or reservations, visit the company website at www.ritzcarlton.com, for the latest company updates, visit news.marriott.com and to join the live conversation, use #RCMemories and follow along on Facebook, X, and Instagram. The Ritz-Carlton Hotel Company, L.L.C. is a wholly-owned subsidiary of Marriott International, Inc. (NASDAQ:MAR). The Ritz-Carlton is proud to participate in Marriott Bonvoy^®, the global travel program from Marriott International. The program offers members an extraordinary portfolio of global brands, exclusive experiences on Marriott Bonvoy Moments and unparalleled benefits including complimentary nights and Elite status recognition. To enroll for free or for more information about the program, visit marriottbonvoy.com. The Ritz-Carlton is committed to supporting the destinations where it operates through Community Footprints, the company’s social and environmental responsibility program.

RIYADH, Nov. 6, 2025 /PRNewswire/ — The eyes of the global industrial community turn toward the Saudi capital, Riyadh, which is preparing to host the first edition of Industrial Transformation Saudi Arabia, taking place from December 1 to 3, 2025. The event is organized by the Ministry of Industry and Mineral Resources, in cooperation with Deutsche Messe AG of Germany and Riyadh Exhibitions Company Ltd.

Industrial Transformation Saudi Arabia 2025: uniting global leaders to connect, innovate, and lead Saudi Arabia’s industrial transformation journey. December 1 to 3

The exhibition represents an extension of a global journey that began in 1947 in Hannover, Germany, where the first edition of the world’s most prominent industrial fair was launched. Since then, it has become an international platform that brings together industrial leaders and innovators from around the world to showcase the latest technologies and transformations in automation, artificial intelligence, energy, and advanced manufacturing.

From Hannover, where it all began, to Türkiye, and later to China, which hosted its Asian edition, the journey of “Industrial Transformation” continues across continents — now reaching the Kingdom of Saudi Arabia, set to become the new hub of global industrial transformation in the Middle East. This expansion underscores the Kingdom’s growing role in shaping the future of industry, adopting Fourth Industrial Revolution technologies, and solidifying its position as a global center for innovation and industrial knowledge.

In its Saudi edition, the exhibition serves as a strategic milestone in the Kingdom’s path toward smart industry, bringing together local and international companies, experts, and investors in a dynamic environment that fosters collaboration and strategic partnerships. It also highlights the Ministry of Industry and Mineral Resources’ achievements in expanding the national industrial base, enhancing local content, and localizing supply chains — all in alignment with Saudi Vision 2030, which aims to build an integrated and sustainable industrial economy.

Industrial Transformation Saudi Arabia stands as a bridge between Germany’s long-standing industrial expertise and the Kingdom’s forward-looking ambition to build the industry of the future. From the factories that defined precision and quality in Europe to the megaprojects taking shape across Saudi Arabia today, the convergence of expertise and innovation reaffirms that the future of industry is being built in Saudi Arabia.

As the opening of the exhibition in December 2025 approaches, the global industrial community eagerly anticipates what Riyadh will unveil in advanced industrial transformation and smart manufacturing — reaffirming the Kingdom’s position as a world-class destination for industrial innovation and a key partner in shaping the future of global industry.

Visitor Registration at Saudi Industrial Transformation Event

AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange

ZURICH, Nov. 6, 2025 /PRNewswire/ — The Adecco Group (SIX: ADEN), today announces the appointment of Valentina Ficaio as chief financial officer (CFO) and member of the executive committee, from January 1, 2026. She will succeed Coram Williams who has decided to step down and will assume the role of CFO for a company in the automotive sector in Germany in the New Year. Coram joined the Adecco Group in 2020.

The Adecco Group, Valentina Ficaio

Valentina, who is Italian, joined the Adecco Group as CFO Iberia in 2019 and then became regional CFO for Southern and Eastern Europe, Middle East and Northern Africa. She is now group senior vice president finance, leading financial planning, controllership and strategy. Prior to joining the Adecco Group, Valentina held CFO roles in the automotive industry and automotive financing and banking. She has a business and managerial economics degree from Luiss Guido Carli University, Rome.

Denis Machuel, CEO of the Adecco Group, commented: “Valentina has deep knowledge of our business, people and customers as well as very strong financial and strategic acumen. I congratulate her on her appointment and look forward to our collaboration as she builds on the strong foundations she and the team have developed in recent years. She will play a key role in shaping the next phase of our journey, ensuring long term value creation for our stakeholders.”

“It has been an absolute pleasure to work alongside Coram. He has guided us through a period of significant transformation, and we warmly thank him for his outstanding contribution. We wish him all the best as he assumes a role that connects to his deep passion for cars.”

Coram said: “After 5 years with the group, I have decided to step down to return to my roots in the automotive sector, closer to family in my adopted home of Germany. It has been a privilege to be the CFO of this great company and I am proud of the transformation that I have been a part of. I’d like to thank the Board of Directors, executive committee and the talented teams around the world for their support during my tenure. Valentina is the ideal candidate for the role; I know that she will help drive the group forward.”

Valentina added: “It is an honour to take on this role in a company that I love. What we do really matters – making a positive impact on the lives of millions of people everyday. Having been part of Coram’s leadership team in the last years, I look forward to the continued collaboration with a strong team, as we continue to transform in line with accelerated market developments.

“I look forward to working with Denis and the executive committee to ensure that we continue to build a company where our people can thrive and we secure profitable growth and create shareholder value as we continue to innovate in a changing world of work.”

Please view full press release and biography here.

For further information please contact:

About the Adecco Group
The Adecco Group is the world’s leading talent and technology expertise company. Our purpose is making the future work for everyone. Through our three global business units – Adecco, Akkodis and LHH – across 60 countries, we enable sustainable and lifelong employability for individuals, deliver digital and engineering consulting solutions to power transformation and empower organisations to optimise their workforces. The Adecco Group leads by example and is committed to fostering sustainable employability and supporting resilient economies and communities. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN).
https://www.adeccogroup.com/